Welcome to our dedicated page for Envveno Med SEC filings (Ticker: NVNBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NVNBW SEC filings page on Stock Titan aggregates regulatory documents connected to ENVVENO MEDICAL CP WT 26 and its underlying issuer, enVVeno Medical Corporation. These filings, drawn from the SEC’s EDGAR system, include Forms 8-K, Definitive Proxy Statements on Schedule 14A, and references to shelf registration statements and prospectus supplements. Together, they provide a detailed record of how the company reports material events, stockholder actions, capital raising arrangements, and regulatory developments.
Form 8-K filings from 2025 illustrate several important themes. One 8-K dated October 10, 2025 discloses a Nasdaq notice that the company’s common stock no longer met the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market, and explains the 180-day compliance period, possible additional 180-day extension, and the potential role of a reverse stock split in curing the deficiency. Later 8-K filings dated December 12, 2025 report the results of the 2025 Annual Meeting of Stockholders, including director elections, an advisory vote on executive compensation, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, the rejection of the 2025 Equity Incentive Plan, and stockholder authorization for the Board of Directors to implement a reverse stock split within a specified ratio range.
Another 8-K dated October 30, 2025 describes an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., under which the company may sell shares of its common stock from time to time as at-the-market equity offerings pursuant to an effective Form S-3 registration statement and a filed prospectus supplement. This filing also lists related exhibits, including the agreement itself and a legal opinion on the validity of the shares. An 8-K dated November 20, 2025 details an amendment to the company’s Amended and Restated Bylaws, revising the quorum requirement for stockholder meetings to a specified percentage of voting power, subject to applicable law and charter provisions.
Regulatory and product matters appear in an 8-K dated November 13, 2025, which reports that the company issued a press release about an unfavorable FDA appeal decision on its Premarket Approval application for VenoValve®, described as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The company notes that the press release is furnished as an exhibit, and the related Definitive Proxy Statement discusses a broader appeal process and its implications for both VenoValve and enVVe, a next generation transcatheter replacement venous valve.
On this NVNBW filings page, Stock Titan presents these documents with AI-powered summaries that help explain the significance of each filing. Investors can quickly see how stockholder votes affected equity incentive plans and reverse stock split authority, how the company structures at-the-market equity offerings, and how listing compliance issues and FDA-related outcomes are disclosed. The page also surfaces information relevant to monitoring governance practices, auditor relationships, bylaw changes, and other material events reported by enVVeno Medical Corporation in connection with the security associated with NVNBW.
enVVeno Medical Corp’s chief executive officer and director, Robert A. Berman, reported insider transactions involving both common stock and equity awards. The Form 4 discloses a disposition of 22,236 shares of common stock, and a related filing shows changes in his derivative holdings.
In addition, 200,000 restricted stock units that were granted to him on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan were voluntarily surrendered and cancelled on December 16, 2025. These units were subject to vesting based on specified performance milestones, which were not achieved, so the unvested awards were given up and no longer provide rights to common shares.
enVVeno Medical Corp executive Hamed Alavi, the company’s Chief Technology Officer, reported a change in his equity holdings. A Form 4 filing shows that 50,000 restricted stock units were surrendered and cancelled at a price of $0. These units were originally issued on November 30, 2021 under the Amended and Restated 2016 Omnibus Incentive Plan and were subject to performance-based vesting conditions.
The filing explains that the specified performance milestones were not achieved, and therefore the unvested restricted stock units were voluntarily cancelled. Following this transaction, the number of derivative securities of this type beneficially owned by Alavi is reported as 0.
enVVeno Medical Corp executive reports cancellation of equity award. SVP & Chief Medical Officer Dr. Marc Glickman filed a beneficial ownership report showing that 100,000 restricted stock units were surrendered and cancelled after specified performance milestones tied to the award were not achieved. The units were originally granted on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan and a Restricted Stock Unit Agreement, and had been scheduled to expire on November 30, 2031. Following this transaction dated December 16, 2025, Dr. Glickman reports direct ownership of 1,600 shares of common stock and no remaining derivative securities from this RSU grant.
enVVeno Medical Corp reported that director Francis Duhay received an award of 135,883 stock options on December 11, 2025. The options allow him to buy the company's common stock at an exercise price of $0.325 per share and expire on December 11, 2035.
The award was granted under the company's Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during 2026. Following this grant, he beneficially owns 135,883 derivative securities directly.
enVVeno Medical Corp reported a new stock option grant to a director. On December 11, 2025, the director received 135,883 stock options with an exercise price of $0.325 per share, expiring on December 11, 2035.
The options were issued under the Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
enVVeno Medical Corp director Matthew M. Jenusaitis reported receiving a grant of stock options in an SEC Form 4. On December 11, 2025, he was issued 135,883 stock options with an exercise price of $0.325 per share under the company’s Amended and Restated 2016 Omnibus Incentive Plan, as amended. These options relate to 135,883 shares of common stock and expire on December 11, 2035.
The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year. Following this grant, Jenusaitis beneficially owns 135,883 derivative securities, held directly.
enVVeno Medical Corp director Sanjay Shrivastava reported receiving stock options covering 135,883 shares of common stock. The options were granted on 12/11/2025 with an exercise price of $0.325 per share, expire on 12/11/2035, and were issued under the company’s Amended and Restated 2016 Omnibus Incentive Plan. The options were awarded at no cost and are held directly.
The award is subject to time-based vesting, with the 135,883 options scheduled to vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
enVVeno Medical Corp director Francis Duhay reported selling 4,900 shares of common stock on December 11, 2025 at a weighted-average price of $0.3556 per share. The sale was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573. After this transaction, the director beneficially owns 92,544 shares of enVVeno Medical common stock. The filing states that the trade was completed under a Rule 10b5-1 trading plan that the reporting person adopted in June 2025, which is a pre-arranged plan for trading company stock.
enVVeno Medical Corporation reported the results of its 2025 Annual Meeting of Stockholders. A total of 11,058,255 shares of common stock were represented in person or by proxy out of 20,216,176 shares outstanding and entitled to vote as of October 17, 2025, representing 54.70% of the voting power.
Stockholders voted on the election of two directors and several additional proposals. For the board seats, Matthew M. Jenusaitis received 3,468,484 votes for and 1,796,053 votes withheld, while Robert A. Berman received 4,727,591 votes for and 536,946 votes withheld. The filing also lists detailed vote totals for four other proposals, each showing the number of votes for, against, abstentions, and broker non-votes, providing transparency into stockholder participation and preferences.
enVVeno Medical Corporation is asking stockholders to approve authority for a reverse stock split of its common stock, at a ratio between one-for-five and one-for-thirty-five, to be implemented at the Board’s discretion if approved. The company currently has 20,216,176 shares outstanding; for example, at a one-for-five ratio this would become approximately 4,043,235 shares. The Board states its main goal is to lift the share price above Nasdaq’s $1.00 minimum bid requirement after receiving notice that the stock traded below that level for 30 consecutive business days, with a recent closing price of $0.3297 per share. The reverse split would not change authorized share counts, so it would increase the pool of authorized but unissued shares, and each holder’s ownership percentage is expected to remain about the same aside from fractional-share cashouts. The Board also reduced the quorum requirement for stockholder meetings to thirty three and one-third percent of voting shares outstanding.